# Edwards Lifesciences clinical trials: 128 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 128 trials with Edwards Lifesciences as lead sponsor, 17 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Edwards Lifesciences: 128 rows for $6.40, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/edwards-lifesciences

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 128
- Recruiting or not yet: 17
- Read on: November 19, 2026

## Trials

The 25 newest of 128, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 6, 2026 | NCT07859709 | The CLASP III TR CED Study | Edwards Lifesciences | Observational | Not yet recruiting | Tricuspid Regurgitation, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Tricuspid Valve Insufficiency | 2,350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859709) |
| October 5, 2026 | NCT07858799 | Early Feasibility Study of the Edwards APTURE Transcatheter Shunt System | Edwards Lifesciences | Not applicable | Recruiting | Heart Failure | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858799) |
| August 3, 2026 | NCT07742839 | CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of... | Edwards Lifesciences | Observational | Not yet recruiting | Atrial Appendage | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742839) |
| July 6, 2026 | NCT07684313 | TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study) | Edwards Lifesciences | Observational | Recruiting | Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Tricuspid Valve Disease | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684313) |
| June 2, 2026 | NCT07619872 | KONECT RESILIA Aortic Valved Conduit (AVC) Real-world Study Assessing Safety and Performance | Edwards Lifesciences | Observational | Recruiting | Aortic Valve Disease | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619872) |
| March 12, 2026 | NCT07466745 | Autus Valve Continued Access Study (CAS) | Edwards Lifesciences | Not applicable | Active not recruiting | Congenital Heart Disease | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07466745) |
| August 13, 2025 | NCT07120048 | Real World Data Collection on the INSPIRIS RESILIA Aortic Valve | Edwards Lifesciences | Observational | Recruiting | Aortic Valve Disease | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07120048) |
| July 11, 2025 | NCT07059793 | MITRIS China Post Market Clinical Follow-up (PMCF) Study | Edwards Lifesciences | Observational | Recruiting | Mitral Valve Replacement | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059793) |
| February 19, 2025 | NCT06834516 | ClearSight Baby Cuff | Edwards Lifesciences | Observational | Completed | Blood Pressure | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06834516) |
| February 18, 2025 | NCT06833476 | TTVR STRONG Under Coverage With Evidence Development (CED) Study | Edwards Lifesciences | Observational | Recruiting | Tricuspid Regurgitation | 2,044 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06833476) |
| August 26, 2024 | NCT06569602 | Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) | Edwards Lifesciences | Observational | Recruiting | Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06569602) |
| December 12, 2023 | NCT06167213 | ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral | Edwards Lifesciences | Not applicable | Not yet recruiting | Mitral Regurgitation, Mitral Valve Disease, Mitral Stenosis | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06167213) |
| March 9, 2023 | NCT05760989 | TRISCEND JAPAN Study | Edwards Lifesciences | Not applicable | Active not recruiting | Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05760989) |
| January 18, 2023 | NCT05688514 | TVMR With the Innovalve System Trial - First In Human Israel | Edwards Lifesciences | Not applicable | Completed | Mitral Valve Regurgitation (Degenerative or Functional) | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05688514) |
| January 17, 2023 | NCT05686317 | ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System | Edwards Lifesciences | Not applicable | Active not recruiting | Heart Failure | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05686317) |
| January 12, 2023 | NCT05682066 | TVMR With the Innovalve System Trial - Pilot in Georgia | Edwards Lifesciences | Not applicable | Completed | Mitral Valve Regurgitation (Degenerative or Functional) | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05682066) |
| September 2, 2022 | NCT05526560 | Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve | Edwards Lifesciences | Observational | Active not recruiting | Mitral Stenosis, Mitral Valve Insufficiency | 504 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05526560) |
| June 3, 2022 | NCT05404880 | INSPIRIS China PMCF Study | Edwards Lifesciences | Observational | Active not recruiting | Aortic Valve Replacement | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05404880) |
| May 18, 2022 | NCT05378386 | ALTERRA Post-Approval Study | Edwards Lifesciences | Observational | Active not recruiting | Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05378386) |
| December 29, 2021 | NCT05172973 | ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | Edwards Lifesciences | Not applicable | Recruiting | Aortic Valve Insufficiency, Aortic Valve Stenosis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05172973) |
| December 29, 2021 | NCT05172960 | ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | Edwards Lifesciences | Not applicable | Recruiting | Aortic Stenosis, Severe | 1,234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05172960) |
| December 23, 2021 | NCT05168826 | China S3 PMS: SAPIEN 3 China Post Market Registry Study | Edwards Lifesciences | Observational | Active not recruiting | Aortic Stenosis, Severe | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05168826) |
| November 3, 2021 | NCT05105477 | Hypotension Prediction Index (HPI) SMART-BP Trial | Edwards Lifesciences | Not applicable | Terminated | Moderate to High-risk Noncardiac Surgery | 407 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05105477) |
| October 19, 2021 | NCT05083403 | HPI (Hypotension Prediction Index) Care Trial | Edwards Lifesciences | Not applicable | Terminated | Cardiopulmonary Bypass Surgery | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05083403) |
| August 18, 2021 | NCT05010746 | TVMR With the Innovalve System Trial - Pilot Study in Italy | Edwards Lifesciences | Not applicable | Active not recruiting | Mitral Valve Regurgitation (Degenerative or Functional) | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05010746) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Not applicable | 82 |
| Observational | 44 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 64 |
| Active not recruiting | 28 |
| Recruiting | 14 |
| Terminated | 11 |
| Withdrawn | 4 |
| Unknown | 3 |
| Not yet recruiting | 3 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Aortic Valve Stenosis | 41 |
| Mitral Valve Insufficiency | 32 |
| Cardiovascular Diseases | 23 |
| Heart Valve Diseases | 20 |
| Heart Diseases | 16 |
| Tricuspid Valve Insufficiency | 14 |
| Aortic Valve Disease | 13 |
| Heart Failure | 11 |
| Gastroesophageal Reflux | 8 |
| Pulmonary Valve Insufficiency | 8 |
| Aortic Valve Insufficiency | 7 |
| Mitral Valve Prolapse | 5 |
| Heart Defects, Congenital | 5 |
| Pulmonary Valve Stenosis | 4 |
| Tetralogy of Fallot | 4 |
| Coronary Artery Disease | 3 |
| Mitral Valve Stenosis | 3 |
| Lymphoma, Follicular | 3 |
| Pulmonary Atresia | 2 |
| Neoplasm Metastasis | 2 |
| Aortic Valve, Calcification of | 2 |
| Constriction, Pathologic | 2 |
| Disease | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Congenital Abnormalities | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [Home cleaning companies in the United States](https://specstream.ai/data/businesses/home-cleaning-companies/united-states)
- [Sake bars in the United States](https://specstream.ai/data/businesses/sake-bars/united-states)
- [Brewing supply stores in the United States](https://specstream.ai/data/businesses/brewing-supply-stores/united-states)
- [Indo Chinese restaurants in the United States](https://specstream.ai/data/businesses/indo-chinese-restaurants/united-states)
- [Solar installers in the United States](https://specstream.ai/data/businesses/solar-installers/united-states)
